Immunoglobulin light chain amyloid (AL amyloid) (AL amyloid)

Immunoglobulin light chain (AL) amyloid consists of misfolded monoclonal light chains that aggregate into soluble precursors and insoluble fibrils, depositing in vital organs such as the heart, kidneys, and liver. This process is driven by a plasma cell dyscrasia that overproduces unstable light chains, which undergo a conformational shift to form beta-sheet rich structures (Merlini et al., 2011, PubMed: 21593444). These aggregates are directly toxic to tissues, particularly cardiomyocytes, leading to rapid organ dysfunction and high mortality (Sanchorawala, 2006, PubMed: 16931720). Therapeutic interventions targeting these fibrils, such as birtamimab and anselamimab, utilize monoclonal antibodies to bind specific epitopes on the misfolded proteins, promoting their clearance by the immune system and preventing further deposition (Gertz et al., 2023, PubMed: 36809345). Unlike chemotherapy which targets the underlying plasma cell clone, these therapies aim to directly remove existing amyloid burden and neutralize circulating toxic species to improve organ-specific outcomes (Comenzo et al., 2012, PubMed: 22677126). The soluble oligomeric precursors are increasingly recognized as the primary drivers of acute cardiotoxicity, making them a critical component of the therapeutic target (Buxbaum et al., 2020, PubMed: 32555334). By facilitating the removal of these deposits, these drugs aim to reverse organ damage that is otherwise irreversible with standard plasma cell-directed therapy. Clinical trials focus on cardiac response and overall survival as primary endpoints for these aggregate-targeting agents. The specificity of these antibodies for misfolded conformations ensures that they do not interfere with the function of normally folded immunoglobulins.

Other names

AL amyloid fibrilsMisfolded immunoglobulin light chainsAmyloid light-chain aggregatesMonoclonal light chain fibrilsSystemic AL amyloidSoluble light chain oligomers

Monoclonal antibodies bind to cryptic epitopes exposed only on misfolded light chains and fibrils, facilitating their clearance through antibody-dependent cellular phagocytosis (ADCP) and neutralizing the proteotoxicity of soluble aggregate precursors.